P-58 Phase II study of irinotecan/cisplatin (IP) induction chemotherapy followed by concurrent twice-daily thoracic radiotherapy (RT) with etoposide/cisplatin (EP) for limited disease small cell lung cancer (LD-SCLC)
Keyword(s):
Phase Ii
◽